抗体-药物结合物（ADC）由理想的单克隆抗体、活性细胞毒性药物和合适的连接剂组成。抗体和细胞毒性药物之间的适当连接物提供特异性桥，从而帮助抗体选择性地将细胞毒性药物递送至肿瘤细胞，并在肿瘤部位精确地释放细胞毒性药物
3-(2-(3-Methoxy-3-oxopropoxy)ethoxy)propanoic acid
1-Bromo-3,6,9,12-tetraoxapentadecan-15-oic acid
4,7,10,13-Tetraoxahexadec-15-yn-1-oic acid
Fmoc-NH-PEG5-CH2COOH
tert-Butyl 1-hydroxy-3,6,9,12,15-pentaoxaoctadecan-18-oate
tert-Butyl 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)acetate
tert-Butyl 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,6,9,12-tetraoxapentadecan-15-oate
1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,6,9,12-tetraoxapentadecan-15-oic acid
tert-Butyl 1-amino-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oate
2-(2-(2-(2-((Tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate
1-Phenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine
1-Hydroxy-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid
4,7,10,13,16,19,22-Heptaoxapentacosane-1,25-dioic acid
17-(Boc-amino)-3,6,9,12,15-pentaoxa-1-heptadecanol
4,7,10,13,16,19,22,25,28-Nonaoxahentriaconta-1,30-diyne
tert-Butyl 1-bromo-2-oxo-6,9,12,15-tetraoxa-3-azaoctadecan-18-oate
tert-Butyl 17-hydroxy-3,6,9,12,15-pentaoxaheptadecan-1-oate
1-Phenyl-2,5,8,11,14-pentaoxahexadecan-16-yl methanesulfonate
14-Amino-3,6,9,12-tetraoxatetradecan-1-oic acid
tert-Butyl 1-hydroxy-3,6,9,12,15,18-hexaoxahenicosan-21-oate
3,6,9,12,15,18,21,24,27,30,33-Undecaoxapentatriacontane-1,35-diamine
tert-Butyl 1-hydroxy-3,6,9,12,15,18,21,24,27,30-decaoxatritriacontan-33-oate
3,6,9,12,15,18,21,24,27,30,33,36,39-Tridecaoxahentetracontane-1,41-diol
3,6,9,12-Tetraoxapentadec-14-yn-1-yl methanesulfonate
4,7,10,13,16,19,22,25,28-Nonaoxahentriacontane-1,31-dioic acid
1-Mercapto-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid
tert-Butyl 1-bromo-3,6,9,12-tetraoxapentadecan-15-oate
tert-Butyl 1-chloro-2-oxo-6,9,12,15-tetraoxa-3-azaoctadecan-18-oate
2-(2-(2-Hydroxyethoxy)ethoxy)ethyl methanesulfonate
2-(2-(2-(2-((Tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl methanesulfonate
